ESSA Pharma Inc. (EPIX)
NASDAQ: EPIX
· Real-Time Price · USD
1.93
0.01 (0.52%)
At close: Aug 15, 2025, 3:59 PM
1.93
0.00%
After-hours: Aug 15, 2025, 07:33 PM EDT
Company Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer.
It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer.
The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc.
ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
ESSA Pharma Inc.
| Country | CA |
| IPO Date | Mar 13, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 35 |
| CEO | David Ross Parkinson |
Contact Details
Address: 999 West Broadway Vancouver, BC CA | |
| Website | https://www.essapharma.com |
Stock Details
| Ticker Symbol | EPIX |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001633932 |
| CUSIP Number | 29668H708 |
| ISIN Number | CA29668H7085 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Ross Parkinson M.D. | President, Chief Executive Officer & Director |
| David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA | Chief Financial Officer |
| Peter A. Virsik M.B.A., M.S. | Executive Vice President & Chief Operating Officer |
| Chandtip Chandhasin | Executive |
| Dr. Alessandra Cesano M.D., Ph.D. | Chief Medical Officer & Executive Vice President |
| Erica Osbourne | Executive |
| Erin Rudsinski | Executive |
| Loleta Harris | Executive |
| Neil Thapar | Executive |
| Nkengyal Barber | Executive |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | DEFA14A | Filing |
| Aug 14, 2025 | 8-K | Current Report |
| Aug 13, 2025 | 10-Q | Quarterly Report |
| Aug 11, 2025 | DEFM14A | Filing |
| Aug 07, 2025 | 4 | Filing |
| Aug 07, 2025 | SCHEDULE 13D/A | [Amend] Filing |
| Aug 06, 2025 | DEFA14A | Filing |
| Aug 06, 2025 | 8-K | Current Report |
| Jul 31, 2025 | DEFA14A | Filing |
| Jul 31, 2025 | 8-K | Current Report |